Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that four new sub-analyses from the Praluent (alirocumab) ODYSSEY OUTCOMES cardiovascular (CV) outcomes trial will be presented at the American College of Cardiology’s 68th Annual Scientific Session (ACC.19), held March 16-18, in New Orleans, LA.
The sub-analyses from the 18,924-patient ODYSSEY OUTCOMES trial include: A Featured Clinical Research presentation that evaluates the impact of lowering lipoprotein(a) [Lp(a)] with Praluent on total CV events, independent of low-density lipoprotein cholesterol (LDL-C) reduction. Elevated Lp(a), an inherited lipid disorder, is associated with increased risk of atherosclerosis and CV disease.
An oral presentation that shows Praluent treatment was associated with larger reductions in the risk of major adverse CV events (MACE) and death in patients with polyvascular disease, compared to those without. Polyvascular disease is defined as having an acute coronary syndrome (ACS), plus either concurrent peripheral artery disease or cerebrovascular disease, or both.
Regeneron and Sanofi presentations at ACC.19 from the ODYSSEY clinical trial program and other trials include the following three oral presentations and five poster presentations.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.